BEKE-W
02423
XIAOMI-W
01810
ALI HEALTH
00241
JD HEALTH
06618
MEITUAN-W
03690
(Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | ---- | 1.48%7.24B | ---- | 12.35%16.36B | ---- | -1.38%7.13B | ---- | -11.09%14.56B | ---- | -7.61%7.23B |
Special items of operating revenue | 2.07%17.22B | ---- | -13.56%4.72B | ---- | 11.85%16.87B | ---- | 29.80%5.46B | ---- | -32.07%15.09B | ---- |
Operating income | 2.07%17.22B | 1.48%7.24B | -13.56%4.72B | 12.35%16.36B | 11.85%16.87B | -1.38%7.13B | 29.80%5.46B | -11.09%14.56B | -32.07%15.09B | -7.61%7.23B |
Operating expenses | ||||||||||
Gross profit | ||||||||||
Administrative expenses | 9.42%-5.16B | ---- | 16.76%-1.6B | ---- | 2.62%-5.7B | ---- | -14.01%-1.92B | ---- | 10.48%-5.85B | ---- |
Employee expense | ---- | 7.77%-1.88B | ---- | 1.58%-4.56B | ---- | 16.41%-2.04B | ---- | 7.13%-4.64B | ---- | 24.42%-2.44B |
Depreciation and amortization | ---- | 0.02%-403.69M | ---- | -4.03%-809.4M | ---- | -4.40%-403.78M | ---- | -8.06%-778.05M | ---- | -10.31%-386.78M |
Impairment and provision | 69.59%-303.89M | 67.39%-311.02M | 117.83%1.98M | -19.06%-1.25B | 5.27%-999.16M | 8.67%-953.89M | -54.82%-11.08M | 19.94%-1.05B | -313.23%-1.05B | -303.96%-1.04B |
-Other impairment is provision | 69.59%-303.89M | 67.39%-311.02M | 117.83%1.98M | -19.06%-1.25B | 5.27%-999.16M | 8.67%-953.89M | -54.82%-11.08M | 19.94%-1.05B | -313.23%-1.05B | -303.96%-1.04B |
Operating interest expense | 1.13%-3.14B | 0.20%-2.08B | -8.51%-1.11B | -6.28%-4.3B | -3.91%-3.18B | -1.68%-2.09B | 5.40%-1.02B | 10.45%-4.05B | 9.14%-3.06B | 8.16%-2.05B |
Special items of operating profit | -26.11%-4.98B | -103.01%-2.78B | -16.70%-1.13B | -131.65%-3.1B | -28.44%-3.95B | -51.94%-1.37B | 17.43%-967.93M | -4,935.91%-1.34B | 56.41%-3.07B | -242.93%-902.56M |
Operating profit | 19.76%3.57B | -178.23%-220.19M | -42.79%867M | -13.91%2.33B | 50.42%2.98B | -31.54%281.44M | 538.40%1.52B | -44.23%2.71B | -59.68%1.98B | -82.83%411.13M |
Share of profits of associates | ---- | -35.17%224.76M | ---- | -12.27%584.25M | ---- | 49.82%346.7M | ---- | -53.88%665.98M | ---- | -68.53%231.41M |
Special items of earning before tax | -19.27%151.55M | 49.25%2.27B | -37.76%120.15M | ---- | -13.30%187.73M | --1.52B | 3,439.30%193.05M | ---- | 137.09%216.53M | ---- |
Earning before tax | 17.45%3.72B | 5.79%2.27B | -42.22%987.14M | -13.58%2.92B | 44.13%3.16B | 234.11%2.15B | 603.55%1.71B | -46.44%3.38B | -56.09%2.2B | -79.47%642.54M |
Tax | -34.78%-414.72M | 35.04%-159.4M | 64.14%-100.57M | 55.80%-162.54M | -58.71%-307.7M | -5,388.47%-245.39M | -1,811.15%-280.44M | 60.62%-367.69M | 71.55%-193.88M | 101.08%4.64M |
After-tax profit from continuing operations | 15.58%3.3B | 11.06%2.11B | -37.92%886.58M | -8.43%2.76B | 42.72%2.86B | 193.80%1.9B | 525.89%1.43B | -43.97%3.01B | -53.65%2B | -76.01%647.18M |
Earning after tax | 15.58%3.3B | 11.06%2.11B | -37.92%886.58M | -8.43%2.76B | 42.72%2.86B | 193.80%1.9B | 525.89%1.43B | -43.97%3.01B | -53.65%2B | -76.01%647.18M |
Minority profit | 770.13%336.65K | 565.15%307K | 5,906.14%347.41K | 1,360.62%2.85M | 119.07%38.69K | 65.26%-66K | 107.19%5.78K | -113.76%-226K | 85.31%-202.86K | 91.82%-190K |
Profit attributable to shareholders | 15.57%3.3B | 11.04%2.11B | -37.94%886.23M | -8.53%2.75B | 42.71%2.86B | 193.72%1.9B | 525.67%1.43B | -43.95%3.01B | -53.66%2B | -76.03%647.37M |
Basic earnings per share | 15.63%0.37 | 14.29%0.24 | -37.50%0.1 | -14.29%0.3 | 33.33%0.32 | 200.00%0.21 | 700.00%0.16 | -51.39%0.35 | -58.62%0.24 | -80.56%0.07 |
Diluted earnings per share | ||||||||||
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.